Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL20606195 | 0.98 | NOTUM (0.36) | NOTUMGLS | |
| SCHEMBL17099612 | 0.83 | GLS (0.49) | GLS | |
| SCHEMBL17099610 | 0.83 | GLS (0.49) | GLS | |
| SCHEMBL17099611 | 0.83 | GLS (0.49) | GLS | |
| SCHEMBL11184972 | 0.79 | MAPT (0.41) | — | |
| SCHEMBL11184969 | 0.79 | MAPT (0.41) | — | |
| SCHEMBL29106339 | 0.76 | NOTUM (0.37) | NOTUMGLS | |
| SCHEMBL610831 | 0.72 | — | — | |
| SCHEMBL29451087 | 0.72 | — | — | |
| SCHEMBL1403947 | 0.71 | CHRNB2 (0.39) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072330-A1 | KIT INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | LUNAC THERAPEUTICS LTD (GB) | 2024-09-05 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-11479546-B2 | Antimalarial hexahydropyrimidine analogues | UCB Biopharma SRL | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479546-B2 | Antimalarial hexahydropyrimidine analogues | G6PD, DPYD, DHODH | NOTUM 4786/4885GLS 1023/4885 |
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F7 | NOTUM 1862/4885GLS 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.